Catalog No.: PC-25026Not For Human Use, Lab Use Only.
JNT-517 (Repinatrabit, JNT517) is a highly selective, first-in-class, orally bioavailable inhibitor of SLC6A19 (B0AT1) with IC50 of 47 nM against human SLC6A19 in the isoleucine transport assay.
JNT-517 (Repinatrabit, JNT517) is a highly selective, first-in-class, orally bioavailable inhibitor of SLC6A19 (B0AT1) with IC50 of 47 nM against human SLC6A19 in the isoleucine transport assay. JNT-517 (Repinatrabit) potently inhibitsthe transport of glutamine in human intestinal epithelial cells with endogenous expression levels of SLC6A19 (IC50 = 81 nM). JNT-517 (Repinatrabit) does not inhibit either SLC1A5, SLC7A5, or SLC6A8 at 35 uM. JNT-517 (Repinatrabit) also shows negligible activity against mouse SLC6A19 (IC50>11.8 uM). JNT-517 (Repinatrabit) is found to be safe and well tolerated and increased the urinary excretion of Phe in a phase 1 healthy volunteer study.
